1
|
Navarro Matilla B, Ortiz Romero PL, Pujol Vallverdú RM, Combalia Escudero A, Zapata Paz I, González Barca E, Muniesa Montserrat C, Morillo Andújar M, Pérez Ferriols A, Román Curto C, Fernández de Misa Cabrera R, Hospital Gil M, Marín Niebla A, Rios Rull PJ, de la Cruz Vicente F, Izu Belloso RM, Martín García-Sancho A, Parera Amer ME, Córdoba Mascuñano R, Ramón Quiles MD, Saus Carreres A, Del Campo García R, Machan S, Viguera Ester P, Blanco Garnelo J. Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage. Actas Dermosifiliogr 2024; 115:119-129. [PMID: 37689349 DOI: 10.1016/j.ad.2023.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Revised: 08/04/2023] [Accepted: 08/08/2023] [Indexed: 09/11/2023] Open
Abstract
BACKGROUND AND OBJECTIVE The cost of treating cutaneous T-cell lymphoma (CTCL) in Spain is unknown. With the advent of new treatments, it is more important than ever to gain an accurate picture of the true costs involved. The MICADOS study had 2 primary objectives: 1)to evaluate the impact of CTCL on patient quality of life, and 2)to evaluate the costs associated with the disease. This article reports the results of the cost analysis. METHODS We estimated the cost of treating CTCL over a period of 1year from the perspective of the Spanish National Health System. Twenty-three dermatologists and hematologists from 15 public hospitals analyzed data for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS). RESULTS A total of 141 patients (57.4% male) with a mean age of 63.6 years (95%CI: 61.4-65.7 years) were included. The mean direct annual cost of treating CTCL was €34,214 per patient. The corresponding costs by stage were €11,952.47 for stageI disease, €23,506.21 for stageII disease, €38,771.81 for stageIII disease, and €72,748.84 for stageIV disease. The total direct annual cost of treating MF/SS in public hospitals in Spain was estimated at €78,301,171; stageI disease accounted for 81% of all costs, stageII for 7%, and stagesIII andIV for 6% each. CONCLUSIONS The MICADOS study offers an accurate picture of the direct cost of treating CTCL in patients with MF/SS in Spain and shows that costs vary significantly according to disease stage. Patient-borne and indirect costs should be analyzed in future studies.
Collapse
Affiliation(s)
- B Navarro Matilla
- Departamento de Hematología, Hospital Universitario Puerta de Hierro, Madrid, España
| | - P L Ortiz Romero
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, España
| | | | - A Combalia Escudero
- Departamento de Dermatología, Hospital Universitario Clínic i Provincial, Barcelona, España
| | - I Zapata Paz
- Departamento de Radiación Oncológica, Hospital Universitario Puerta de Hierro, Madrid, España
| | - E González Barca
- Departamento de Hematología, Institut Catalá d'Oncología, Hospitalet de Llobregat, Barcelona, España
| | - C Muniesa Montserrat
- Departamento de Dermatología, Hospital Universitario de Bellvitge, Barcelona, España
| | - M Morillo Andújar
- Departamento de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - A Pérez Ferriols
- Departamento de Dermatología, Hospital General Universitario de Valencia, Valencia, España
| | - C Román Curto
- Departamento de Dermatología, Hospital General Universitario de Salamanca, Salamanca, España
| | - R Fernández de Misa Cabrera
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España
| | - M Hospital Gil
- Departamento de Dermatología, Hospital Universitario Puerta de Hierro, Madrid, España
| | - A Marín Niebla
- Departamento de Hematología, Hospital Universitario Vall d'Hebron/VHIO, Barcelona, España
| | - P J Rios Rull
- Departamento de Hematología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, España
| | - F de la Cruz Vicente
- Departamento de Hematología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - R M Izu Belloso
- Departamento de Dermatología, Hospital de Basurto, Bilbao, España
| | - A Martín García-Sancho
- Departamento de Hematología, Hospital General Universitario de Salamanca, Salamanca, España
| | - M E Parera Amer
- Departamento de Dermatología, Hospital Son Llàtzer, Palma de Mallorca, España
| | - R Córdoba Mascuñano
- Departamento de Hematología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
| | - M D Ramón Quiles
- Departamento de Dermatología, Hospital Clínico Universitario, Valencia, España
| | - A Saus Carreres
- Departamento de Hematología, Hospital Clínico Universitario, Valencia, España
| | - R Del Campo García
- Departamento de Hematología, Hospital Son Llàtzer, Palma de Mallorca, España
| | - S Machan
- Departamento de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, España
| | - P Viguera Ester
- Departamento Médico, Kyowa Kirin Farmacéutica, S.L., Madrid, España
| | - J Blanco Garnelo
- Departamento Médico, Kyowa Kirin Farmacéutica, S.L., Madrid, España.
| |
Collapse
|
2
|
Navarro Matilla B, Ortiz Romero PL, Pujol Vallverdú RM, Combalia Escudero A, Zapata Paz I, González Barca E, Muniesa Montserrat C, Morillo Andújar M, Pérez Ferriols A, Román Curto C, Fernández de Misa Cabrera R, Hospital Gil M, Marín Niebla A, Rios Rull PJ, de la Cruz Vicente F, Izu Belloso RM, Martín García-Sancho A, Parera Amer ME, Córdoba Mascuñano R, Ramón Quiles MD, Saus Carreres A, Del Campo García R, Machan S, Viguera Ester P, Blanco Garnelo J. [Translated article] Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage. Actas Dermo-Sifiliográficas 2024; 115:T119-T129. [PMID: 38048944 DOI: 10.1016/j.ad.2023.11.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 08/08/2023] [Indexed: 12/06/2023] Open
Abstract
BACKGROUND AND OBJECTIVE The cost of treating cutaneous T-cell lymphoma (CTCL) in Spain is unknown. With the advent of new treatments, it is more important than ever to gain an accurate picture of the true costs involved. The MICADOS study had 2 primary objectives: 1)to evaluate the impact of CTCL on patient quality of life, and 2)to evaluate the costs associated with the disease. This article reports the results of the cost analysis. METHODS We estimated the cost of treating CTCL over a period of 1year from the perspective of the Spanish National Health System. Twenty-three dermatologists and hematologists from 15 public hospitals analyzed data for adult patients with mycosis fungoides (MF) or Sézary syndrome (SS). RESULTS A total of 141 patients (57.4% male) with a mean age of 63.6 years (95%CI: 61.4-65.7 years) were included. The mean direct annual cost of treating CTCL was €34,214 per patient. The corresponding costs by stage were €11,952.47 for stageI disease, €23,506.21 for stageII disease, €38,771.81 for stageIII disease, and €72,748.84 for stageIV disease. The total direct annual cost of treating MF/SS in public hospitals in Spain was estimated at €78,301,171; stageI disease accounted for 81% of all costs, stageII for 7%, and stagesIII andIV for 6% each. CONCLUSIONS The MICADOS study offers an accurate picture of the direct cost of treating CTCL in patients with MF/SS in Spain and shows that costs vary significantly according to disease stage. Patient-borne and indirect costs should be analyzed in future studies.
Collapse
Affiliation(s)
- B Navarro Matilla
- Departamento de Hematología, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | - P L Ortiz Romero
- Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | | | - A Combalia Escudero
- Departamento de Dermatología, Hospital Universitario Clínic i Provincial, Barcelona, Spain
| | - I Zapata Paz
- Departamento de Radiación Oncológica, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | - E González Barca
- Departamento de Hematología, Institut Catalá d'Oncología, Hospitalet de Llobregat, Barcelona, Spain
| | - C Muniesa Montserrat
- Departamento de Dermatología, Hospital Universitario de Bellvitge, Barcelona, Spain
| | - M Morillo Andújar
- Departamento de Dermatología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - A Pérez Ferriols
- Departamento de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain
| | - C Román Curto
- Departamento de Dermatología, Hospital General Universitario de Salamanca, Salamanca, Spain
| | - R Fernández de Misa Cabrera
- Departamento de Dermatología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - M Hospital Gil
- Departamento de Dermatología, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | - A Marín Niebla
- Departamento de Hematología, Hospital Universitario Vall d'Hebron/VHIO, Barcelona, Spain
| | - P J Rios Rull
- Departamento de Hematología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
| | - F de la Cruz Vicente
- Departamento de Hematología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - R M Izu Belloso
- Departamento de Dermatología, Hospital de Basurto, Bilbao, Spain
| | - A Martín García-Sancho
- Departamento de Hematología, Hospital General Universitario de Salamanca, Salamanca, Spain
| | - M E Parera Amer
- Departamento de Dermatología, Hospital Son Llàtzer, Palma de Mallorca, Spain
| | - R Córdoba Mascuñano
- Departamento de Hematología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M D Ramón Quiles
- Departamento de Dermatología, Hospital Clínico Universitario, Valencia, Spain
| | - A Saus Carreres
- Departamento de Hematología, Hospital Clínico Universitario, Valencia, Spain
| | - R Del Campo García
- Departamento de Hematología, Hospital Son Llàtzer, Palma de Mallorca, Spain
| | - S Machan
- Departamento de Dermatología, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - P Viguera Ester
- Departamento Médico, Kyowa Kirin Farmacéutica, S.L., Madrid, Spain
| | - J Blanco Garnelo
- Departamento Médico, Kyowa Kirin Farmacéutica, S.L., Madrid, Spain.
| |
Collapse
|
3
|
Lopez Valcarcel M, Zapata Paz I, Velasco Jimenez J, Benlloch Rodriguez R, Gil Haro B, Hernandez Miguel M, Cordoba Largo S, Romero Fernandez J. Stereotactic ablative radiotherapy (SABR) for oligometastatic lymph node relapse in prostate cancer. EUR UROL SUPPL 2021. [DOI: 10.1016/s2666-1683(21)03136-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
4
|
Gil Haro B, Santana Jiménez S, Zapata Paz I, Molerón Mancebo R, Rodríguez Romero R, Sánchez Rubio P, Velasco Jiménez J, Benlloch Rodríguez R, Hernández Miguel M, López Valcárcel M, Córdoba Largo S, Engel O, De La Fuente Alonso C, Romero Fernández J. PO-1441 Single fraction Lumbopelvic Bone Irradiation with Tomotherapy for widespread bone metastases. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07892-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Rodríguez RB, Fernández JR, Díaz RC, García SR, Rubio PS, García SS, Montesinos IM, Paz IZ, Valcárcel ML. EP-2167 Radiosensitizing effect of eribulin mesylate in human cervical carcinoma cells in vitro. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32587-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Cardona Arboniés J, Rodríguez Alfonso B, Mucientes Rasilla J, Martínez Ballesteros C, Zapata Paz I, Prieto Soriano A, Carballido Rodriguez J, Mitjavila Casanovas M. 18 F-Choline PET/CT scan in staging and biochemical recurrence in prostate cancer patients: Changes in classification and radiotherapy planning. Rev Esp Med Nucl Imagen Mol 2017. [DOI: 10.1016/j.remnie.2017.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Cardona Arboniés J, Rodríguez Alfonso B, Mucientes Rasilla J, Martínez Ballesteros C, Zapata Paz I, Prieto Soriano A, Carballido Rodriguez J, Mitjavila Casanovas M. 18F-Choline PET/CT scan in staging and biochemical recurrence in prostate cancer patients: Changes in classification and radiotherapy planning. Rev Esp Med Nucl Imagen Mol 2017; 36:292-297. [PMID: 28366421 DOI: 10.1016/j.remn.2017.02.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2016] [Revised: 02/13/2017] [Accepted: 02/14/2017] [Indexed: 10/19/2022]
Abstract
OBJECTIVE To evaluate the role of the 18F-Choline PET/CT in prostate cancer management when detecting distant disease in planning radiotherapy and staging and to evaluate the therapy changes guided by PET/TC results. MATERIAL AND METHODS A retrospective evaluation was performed on 18F-Choline PET/CT scans of patients with prostate cancer. Staging and planning radiotherapy scans were selected in patients with at least 9 months follow up. There was a total of 56 studies, 33 (58.93%) for staging, and 23 (41.07%) for planning radiotherapy. All scans were obtained using a hybrid PET/CT scanner. The PET/CT acquisition protocol consisted of a dual-phase procedure after the administration of an intravenous injection of 296-370MBq of 18F-Choline. RESULTS There were 43 out of 56 (76.8%) scans considered as positive, and 13 (23.2%) were negative. The TNM staging was changed in 13 (23.2%) scans. The PET/CT findings ruled out distant disease in 4 out of 13 scans, and unknown distant disease was detected in 9 (69.3%) scans. CONCLUSIONS 18F-Choline PET/CT is a useful technique for detecting unknown distant disease in prostate cancer when staging and planning radiotherapy. The inclusion of 18F-choline PET/CT should be considered in prostate cancer management protocols.
Collapse
Affiliation(s)
- J Cardona Arboniés
- Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro, Majadahonda, España.
| | - B Rodríguez Alfonso
- Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro, Majadahonda, España
| | - J Mucientes Rasilla
- Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro, Majadahonda, España
| | | | - I Zapata Paz
- Servicio de Oncología Radioterápica, Hospital Universitario Puerta de Hierro, Majadahonda, España
| | - A Prieto Soriano
- Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro, Majadahonda, España
| | | | - M Mitjavila Casanovas
- Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro, Majadahonda, España
| |
Collapse
|
8
|
Benlloch Rodríguez R, Romero Fernandez J, Rincón Cruz D, Martín Hernández G, García-Berrocal J, Vaquero Barrón B, Zapata Paz I, Alvarez montero O, Gonzalo Ruiz S, De la Torre Tomas A. EP-1051: Long-term quality of life and second tumours in T1N0 glottic cancer treated with radical radiotherapy. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32301-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
López Valcárcel M, Zapata Paz I, Valcárcel Sancho F, Amaya Escobar E, Tavera Pomata P, Molerón Mancebo R, Velasco Jiménez J, de La Torre Tomás A. Stereotactic body radiotherapy for early lung cancer and lung metastases. Rep Pract Oncol Radiother 2013. [DOI: 10.1016/j.rpor.2013.03.324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|